Impact of Bone Mineral Density and Bone Structural Properties on Postmenopausal Women With Rheumatoid Arthritis in Japan: A Cross-Sectional Study

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2024 Aug 22

PMID 39171014

Authors

Yasuyuki Omichi

Fumio Shinomiya

Noriaki Mima

Jun Hirose

Tsutomu Enomoto

Tomohiro Goto

Shunji Nakano

Tetsuya Enishi

Masatoshi Morimoto

Koichi Sairyo

Affiliations

Soon will be listed here.

Abstract

Introduction There has been no study on bone structural properties in postmenopausal women with rheumatoid arthritis (RA) in Japan. This study investigated bone mineral density (BMD) and bone structural properties in Japanese postmenopausal women with RA. Methods The study had a cross-sectional design and included 119 postmenopausal women aged 50-80 years with RA symptoms for more than five years. BMD, trabecular bone score (TBS), and results of hip structure analysis (HSA) were measured on dual-energy X-ray absorptiometry scans. The control group consisted of 288 women aged 50-80 years without RA. The RA group and control group using bisphosphonates were compared after propensity score matching for age, body mass index, and fracture history. Women in the RA group were also compared according to the use of glucocorticoids (GCs). Results After the propensity matching score, there were no other significant differences in BMD, TBS, and HSA parameters between the RA group and the control group. In the RA group, the TBS was lower in patients on GCs than those not on GCs (1.272 vs 1.313, p=0.008). There were no other significant differences in BMD and HSA parameters between patients in the RA group according to the use of GCs. Conclusion Although there were no differences in BMD, the TBS was lower in patients on GCs than those not on GCs in the RA group. It is thus important for physicians who administer GCs to treat patients with RA to be aware of not only BMD but also TBS.

References

Hua C, Buttgereit F, Combe B . Glucocorticoids in rheumatoid arthritis: current status and future studies. RMD Open. 2020; 6(1). PMC: 7046968. DOI: 10.1136/rmdopen-2017-000536. View

Paggiosi M, Peel N, Eastell R . The impact of glucocorticoid therapy on trabecular bone score in older women. Osteoporos Int. 2015; 26(6):1773-80. DOI: 10.1007/s00198-015-3078-1. View

Smolen J, Landewe R, Bergstra S, Kerschbaumer A, Sepriano A, Aletaha D . EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2022; 82(1):3-18. DOI: 10.1136/ard-2022-223356. View

Omichi Y, Mima N, Wada K, Okada R, Tamaki Y, Hamada D . Can TBS reference values be a valid indicator for clinical vertebral fracture? A cross-sectional study. J Bone Miner Metab. 2023; 42(1):60-68. DOI: 10.1007/s00774-023-01476-1. View

Silva B, Leslie W, Resch H, Lamy O, Lesnyak O, Binkley N . Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res. 2014; 29(3):518-30. DOI: 10.1002/jbmr.2176. View

Choi Y, Chung Y, Suh C, Jung J, Kim H . Trabecular bone score as a supplementary tool for the discrimination of osteoporotic fractures in postmenopausal women with rheumatoid arthritis. Medicine (Baltimore). 2017; 96(45):e8661. PMC: 5690799. DOI: 10.1097/MD.0000000000008661. View

. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001; 285(6):785-95. DOI: 10.1001/jama.285.6.785. View

Omichi Y, Mima N, Okada R, Wada K, Morimoto M, Sairyo K . Identifying vertebral fractures in the Japanese population using the trabecular bone score: a cross-sectional study. BMC Musculoskelet Disord. 2022; 23(1):976. PMC: 9650906. DOI: 10.1186/s12891-022-05839-z. View

Acevedo C, Sylvia M, Schaible E, Graham J, Stanhope K, Metz L . Contributions of Material Properties and Structure to Increased Bone Fragility for a Given Bone Mass in the UCD-T2DM Rat Model of Type 2 Diabetes. J Bone Miner Res. 2018; 33(6):1066-1075. PMC: 6011658. DOI: 10.1002/jbmr.3393. View

10.

Wright N, Lisse J, Beck T, Sherrill D, Mohler M, Bassford T . Rheumatoid arthritis is associated with less optimal hip structural geometry. J Clin Densitom. 2011; 15(1):39-48. PMC: 3221772. DOI: 10.1016/j.jocd.2011.06.003. View

11.

Bergstra S, Sepriano A, Kerschbaumer A, van der Heijde D, Caporali R, Edwards C . Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2022; 82(1):81-94. DOI: 10.1136/ard-2022-223358. View

12.

Shuhart C, Yeap S, Anderson P, Jankowski L, Lewiecki E, Morse L . Executive Summary of the 2019 ISCD Position Development Conference on Monitoring Treatment, DXA Cross-calibration and Least Significant Change, Spinal Cord Injury, Peri-prosthetic and Orthopedic Bone Health, Transgender Medicine, and Pediatrics. J Clin Densitom. 2019; 22(4):453-471. DOI: 10.1016/j.jocd.2019.07.001. View

13.

Fraenkel L, Bathon J, England B, St Clair E, Arayssi T, Carandang K . 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021; 73(7):924-939. PMC: 9273041. DOI: 10.1002/acr.24596. View

14.

Genant H, Wu C, van Kuijk C, Nevitt M . Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993; 8(9):1137-48. DOI: 10.1002/jbmr.5650080915. View

15.

Ulivieri F, Rinaudo L . The Bone Strain Index: An Innovative Dual X-ray Absorptiometry Bone Strength Index and Its Helpfulness in Clinical Medicine. J Clin Med. 2022; 11(9). PMC: 9102586. DOI: 10.3390/jcm11092284. View

16.

Chotiyarnwong P, McCloskey E . Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat Rev Endocrinol. 2020; 16(8):437-447. DOI: 10.1038/s41574-020-0341-0. View

17.

Corrado A, Rotondo C, Mele A, Cici D, Maruotti N, Sanpaolo E . Influence of glucocorticoid treatment on trabecular bone score and bone remodeling regulators in early rheumatoid arthritis. Arthritis Res Ther. 2021; 23(1):180. PMC: 8261978. DOI: 10.1186/s13075-021-02562-3. View

18.

Komatsu N, Takayanagi H . Mechanisms of joint destruction in rheumatoid arthritis - immune cell-fibroblast-bone interactions. Nat Rev Rheumatol. 2022; 18(7):415-429. DOI: 10.1038/s41584-022-00793-5. View

19.

Beck T . Extending DXA beyond bone mineral density: understanding hip structure analysis. Curr Osteoporos Rep. 2007; 5(2):49-55. DOI: 10.1007/s11914-007-0002-4. View

20.

Boers M, Hartman L, Opris-Belinski D, Bos R, Kok M, Da Silva J . Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial. Ann Rheum Dis. 2022; 81(7):925-936. PMC: 9209692. DOI: 10.1136/annrheumdis-2021-221957. View